



PRESS RELEASE
27 November 2020

Cessatech's IPO of units significantly oversubscribed

The subscription period in Cessatech A/S ("Cessatech" or the "Company") IPO of units (shares and consideration free warrants) ended on 24 November 2020. The initial part of the IPO of units was subscribed to a total of approx. DKK 107 million, corresponding to a subscription ratio of approx. 680 percent, and Cessatech will thereby be provided approx. DKK 15.8 million (before issue costs). Through the IPO of units, Cessatech receives approx. 1,270 new shareholders. Settlement notes are scheduled to be sent out today, 27 November 2020. The first day of trading at Spotlight Stock Market is expected to be 16 December 2020. Sedermera Fondkommission is the financial advisor and Markets & Corporate Law Nordic AB is the legal advisor in connection with the capitalization and listing. Nordnet Bank AB has acted as selling agent.

Cessatech's CEO Jes Trygved comments

"We are overwhelmed and incredibly grateful for the great interest that has been shown in our IPO and I would like to take this opportunity to welcome all new shareholders. We have an exciting journey ahead of us and we are now one step closer to making our lead product available on the market."

Subscription and allocation

The initial part of the IPO of units was subscribed to approx. DKK 107 million, including subscription commitments, corresponding to a subscription ratio of approx. 680 percent. Cessatech will thereby be provided a total of approx. DKK 15.8 million before total issue costs, which are estimated to amount to approx. DKK 1.78 million (approx. 11.22 percent of the total initial issue volume). The allocation of units has been decided by the Board of Directors in accordance with the principles stated in the terms in the prospectus. Settlement notes are expected to be sent out today, 27 November 2020. Subscribers who are not allocated any units will not receive a settlement note.

Warrants of series TO 1

The exercise period for the warrants of series TO 1 that were issued in connection with the IPO of units will run from 25 November 2021 until and including 16 December 2021. For each warrant, the warrant holder has the right to subscribe for one (1) new share at a price of DKK 10.00 per new share. If all warrants of series TO 1 are exercised, the Company will be provided an additional approx. DKK 25.2 million before issue costs.

Number of shares and share capital

When the initial part of Cessatech's IPO of units has been registered with the Danish Companies Registration Office, the total number of shares will amount to 3,680,000 shares and the share capital will amount to DKK 736,000. The total number of outstanding warrants of series TO 1 in the Company will amount to 2,520,000.

Listing at Spotlight Stock Market

Cessatech's shares and warrants are planned to be listed at Spotlight Stock Market. The first day of trading in the shares and warrants is projected to be on 16 December 2020. The share will be traded under the ticker name "CESSA", with ISIN code DK0061411964 and the warrant will be traded under the ticker name "CESSA TO 1", with ISIN code DK0061416849.



PRESS RELEASE
27 November 2020

Advisors

Sedermera Fondkommission is the financial advisor to Cessatech in connection with the capitalization and listing at Spotlight Stock Market. Markets & Corporate Law Nordic AB is the legal advisor.

Selling agent

Nordnet Bank AB has acted as selling agent in the IPO of units.

For additional information on the issue of units, please contact:

Sedermera Fondkommission
Phone: +46 (0) 40-615 14 10
E-mail: info@sedermera.se

For more information about Cessatech, please contact:

Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com

This information is information that Cessatech is obliged to publish in accordance to the EU Market Abuse Regulation. The information was provided by the contact person set out above for publication on 27 November 2020.

Cessatech A/S is a Danish pharmaceutical company committed to developing and commercialising evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, being easy to administer, a fast-acting therapeutic effect and being medically approved for children. CT001 is expected to enter late stage clinical development in 2021.

Introduction video: https://cessatech.com/wp-content/uploads/2020/11/CessatechTeaser1_LR.mp4